Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story (Q37411117)

20 August 2017

1 reference

title

Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story (English)

1 reference

20 August 2017

coronary artery disease

1 reference

Roberto Ferrari

1

1 reference

PubMed ID

19275271

20 August 2017

Kim Fox

series ordinal

2

1 reference

20 August 2017

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

69

1 reference

20 August 2017

3

1 reference

20 August 2017

265-277

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200969030-00003

20 August 2017

0 references

cites work

Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200969030-00003

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

12 December 2020

The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?

1 reference

12 December 2020

GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico

1 reference

12 December 2020

Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?

1 reference

12 December 2020

Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.

1 reference

12 December 2020

Different effect of antihypertensive drugs on conduit artery endothelial function

1 reference

12 December 2020

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

12 December 2020

Late treatment with ramipril increases survival in old spontaneously hypertensive rats

1 reference

12 December 2020

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

12 December 2020

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

1 reference

12 December 2020

Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study

1 reference

12 December 2020

Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials

1 reference

12 December 2020

Cardiovascular remodeling, apoptosis, and drugs

1 reference

12 December 2020

Secondary prevention of coronary artery disease and the choice of the ACE inhibitor why EUROPA and not PEACE

1 reference

12 December 2020

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

1 reference

12 December 2020

Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril

1 reference

12 December 2020

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

1 reference

12 December 2020

The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice

1 reference

12 December 2020

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

12 December 2020

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

12 December 2020

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collabor

1 reference

12 December 2020

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

1 reference

12 December 2020

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators

1 reference

12 December 2020

RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites

1 reference

12 December 2020

Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome

1 reference

12 December 2020

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

1 reference

12 December 2020

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

1 reference

12 December 2020

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

1 reference

12 December 2020

Pathogenesis of atherosclerosis

1 reference

12 December 2020

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial

1 reference

12 December 2020

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

12 December 2020

Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)

1 reference

12 December 2020

ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: results from the PERTINENT study

1 reference

12 December 2020

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

1 reference

12 December 2020

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

12 December 2020

ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE?

1 reference

12 December 2020

Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol

1 reference

12 December 2020

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

1 reference

12 December 2020

The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

1 reference

12 December 2020

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

12 December 2020

Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE

1 reference

12 December 2020

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

12 December 2020

Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies

1 reference

12 December 2020

Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study

1 reference

12 December 2020

The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice

1 reference

12 December 2020

Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent

1 reference

12 December 2020

Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study

1 reference

12 December 2020

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial

1 reference

12 December 2020

The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data

1 reference

12 December 2020

Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial

1 reference

12 December 2020

10.2165/00003495-200969030-00003

Identifiers

DOI

1 reference

PubMed ID

19275271

Dimensions Publication ID

20 August 2017

0 references

1 reference

PubMed ID

19275271